Gara Jalqabaatti › Haala Adda Ba'uu Lymfhaatikii
Qorannoo klinikaalii Haala Adda Ba'uu Lymfhaatikii Ameerikaa Keessatti hirmaatuu
Qorannoo 7 Haala Adda Ba'uu Lymfhaatikii f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
Naannoon
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
A Prospective Natural History Study of Lymphatic Anomalies
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
1 Day – 100 Years · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05731141A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07285005Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 0 hanga 100 · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT05948943Lymphatic Anomalies Registry for the Assessment of Outcome Data
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT02399527A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 2 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06789913Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Namoota walitti qabaa jiraSadarkaa 2
6 Months – 18 Years · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT05871970Weekly Sirolimus Therapy
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 2 fi ol · Saalaa hunda · Haaromfame 05-Bit-2026 · NCT04861064Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.